Literature DB >> 32372266

The roles of resveratrol on cardiac mitochondrial function in cardiac diseases.

Apiwan Arinno1,2,3, Nattayaporn Apaijai1,2, Siriporn C Chattipakorn1,2, Nipon Chattipakorn4,5,6.   

Abstract

Left ventricular (LV) dysfunction is commonly associated with a variety of health conditions including acute myocardial infarction and obesity/diabetes. In addition, administration of several pharmacological agents such as anticancer, antiviral, and immunosuppressive drugs has been shown to be related with LV dysfunction. The molecular mechanism responsible for LV dysfunction has been extensively studied, and it has been proposed that the overproduction of reactive oxygen species (ROS) plays a crucial role in the regulation of this function. Mitochondria require the balance between ROS production and antioxidants to maintain their appropriate function and to prevent excessive ROS production. Thus, the excessive production of ROS and the reduced scavenging process under any pathological conditions could disrupt mitochondrial function, leading to energy depletion with subsequent cell death. Therefore, maintenance of the balance between oxidative stress and antioxidants is essential. Resveratrol, a stilbene, has been investigated extensively, and potentially used to treat or prevent various cardiovascular diseases. Resveratrol directly upregulates antioxidative capacity by increasing antioxidant genes such as heme oxygenase-1, superoxide dismutase, catalase, and glutathione. In this review, accumulated data from in vitro, ex vivo, and in vivo studies regarding the effects of resveratrol on cardiac mitochondrial function in cardiac pathologies are comprehensively summarized and discussed. Since there is no conclusive available clinical study regarding the effects of resveratrol on cardiac mitochondrial function, this review also aims to encourage more clinical investigations to confirm findings from basic research. This comprehensive review will provide insight regarding the potential mechanistic roles of resveratrol in preventing and/or treating patients with cardiovascular diseases to improve LV function and their health status.

Entities:  

Keywords:  Cardiac ischemia–reperfusion injury; Cardiotoxicity; Chemotherapy; Mitochondria; Resveratrol

Mesh:

Substances:

Year:  2020        PMID: 32372266     DOI: 10.1007/s00394-020-02256-7

Source DB:  PubMed          Journal:  Eur J Nutr        ISSN: 1436-6207            Impact factor:   5.614


  67 in total

Review 1.  Acute myocardial infarction: reperfusion treatment.

Authors:  Flavio Ribichini; William Wijns
Journal:  Heart       Date:  2002-09       Impact factor: 5.994

Review 2.  Mitochondria and heart failure: new insights into an energetic problem.

Authors:  L Chen; A A Knowlton
Journal:  Minerva Cardioangiol       Date:  2010-04       Impact factor: 1.347

3.  Anthracycline Chemotherapy-Induced Cardiotoxicity in Breast Cancer Survivors: A Systematic Review.

Authors:  Katherine J Lin; Cecile A Lengacher
Journal:  Oncol Nurs Forum       Date:  2019-09-01       Impact factor: 2.172

Review 4.  Pathophysiology of ischaemia-reperfusion injury.

Authors:  D L Carden; D N Granger
Journal:  J Pathol       Date:  2000-02       Impact factor: 7.996

Review 5.  Metabolic syndrome and mitochondrial function: molecular replacement and antioxidant supplements to prevent membrane peroxidation and restore mitochondrial function.

Authors:  Garth L Nicolson
Journal:  J Cell Biochem       Date:  2007-04-15       Impact factor: 4.429

6.  Right ventricular dysfunction and organ failure in left ventricular assist device recipients: a continuing problem.

Authors:  Minoo N Kavarana; Melissa S Pessin-Minsley; Jacqueline Urtecho; Katharine A Catanese; Margaret Flannery; Mehmet C Oz; Yoshifumi Naka
Journal:  Ann Thorac Surg       Date:  2002-03       Impact factor: 4.330

7.  Stable free radical scavenging and antiperoxidative properties of resveratrol compared in vitro with some other bioflavonoids.

Authors:  K L Khanduja; Anjana Bhardwaj
Journal:  Indian J Biochem Biophys       Date:  2003-12       Impact factor: 1.918

Review 8.  Mitochondria in the human heart.

Authors:  H Lemieux; C L Hoppel
Journal:  J Bioenerg Biomembr       Date:  2009-04       Impact factor: 2.945

Review 9.  Reperfusion therapy for acute myocardial infarction: Concepts and controversies from inception to acceptance.

Authors:  Klaus Peter Rentrop; Frederick Feit
Journal:  Am Heart J       Date:  2015-08-14       Impact factor: 4.749

Review 10.  A Systematic Review on the Prevalence of Acute Myocardial Infarction in Iran.

Authors:  Jaber Mohseni; Toba Kazemi; Mahmood Hosseinzadeh Maleki; Hossein Beydokhti
Journal:  Heart Views       Date:  2017 Oct-Dec
View more
  4 in total

1.  Ameliorative Potential of Resveratrol in Dry Eye Disease by Restoring Mitochondrial Function.

Authors:  Jingyao Chen; Weijia Zhang; Yixin Zheng; Yanze Xu
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-26       Impact factor: 2.650

2.  Empagliflozin Ameliorates Diabetic Cardiomyopathy via Attenuating Oxidative Stress and Improving Mitochondrial Function.

Authors:  Jinwu Wang; Xinyuan Huang; Hanjie Liu; Yuhang Chen; Peipei Li; Lingling Liu; Jiashen Li; Yangxi Ren; Junping Huang; Erya Xiong; Zhijie Tian; Xiaozhen Dai
Journal:  Oxid Med Cell Longev       Date:  2022-05-09       Impact factor: 7.310

Review 3.  Can resveratrol modulate sirtuins in obesity and related diseases? A systematic review of randomized controlled trials.

Authors:  Gabriela Macedo Fraiz; Aline Rosignoli da Conceição; Darlene Larissa de Souza Vilela; Daniela Mayumi Usuda Prado Rocha; Josefina Bressan; Helen Hermana Miranda Hermsdorff
Journal:  Eur J Nutr       Date:  2021-07-12       Impact factor: 5.614

4.  Impact of Obesity-Induced Inflammation on Cardiovascular Diseases (CVD).

Authors:  Gopi Battineni; Getu Gamo Sagaro; Nalini Chintalapudi; Francesco Amenta; Daniele Tomassoni; Seyed Khosrow Tayebati
Journal:  Int J Mol Sci       Date:  2021-04-30       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.